Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 6 of 6

Publication Record

Connections

Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?
Laster AJ, Tanner SB
(2011) Rheum Dis Clin North Am 37: 323-36, v
MeSH Terms: Bone Density Conservation Agents, Bone and Bones, Estrogen Replacement Therapy, Female, Fractures, Bone, Humans, Middle Aged, Osteoporosis, Postmenopausal, Practice Guidelines as Topic, Risk Factors, Substance Withdrawal Syndrome
Added January 20, 2015
0 Communities
1 Members
0 Resources
11 MeSH Terms
The ethics of placebo in studies with fracture end points in osteoporosis.
Stein CM, Ray WA
(2010) N Engl J Med 363: 1367-70; discussion e21
MeSH Terms: Bone Density Conservation Agents, Female, Fractures, Bone, Humans, Osteoporosis, Postmenopausal, Placebos, Randomized Controlled Trials as Topic
Added December 10, 2013
0 Communities
2 Members
0 Resources
7 MeSH Terms
Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis.
Ryder KM, Tanner SB, Carbone L, Williams JE, Taylor HM, Bush A, Pintea V, Watsky MA
(2010) J Bone Miner Metab 28: 233-9
MeSH Terms: Aged, Biomarkers, Bone Density Conservation Agents, Bone Resorption, Bone and Bones, Calcium, Drug Monitoring, Female, Humans, Hypercalcemia, Hypokinesia, Injections, Subcutaneous, Institutionalization, Male, Middle Aged, Osteogenesis, Osteoporosis, Osteoporosis, Postmenopausal, Persons with Mental Disabilities, Teriparatide, Time Factors, Treatment Outcome
Added January 20, 2015
0 Communities
1 Members
0 Resources
22 MeSH Terms
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R
(2009) J Womens Health (Larchmt) 18: 935-43
MeSH Terms: Adult, Aged, Aged, 80 and over, Bone Density Conservation Agents, Bone Diseases, Metabolic, Combined Modality Therapy, Diphosphonates, Drug Administration Schedule, Drug Substitution, Female, Humans, Ibandronic Acid, Middle Aged, Osteoporosis, Postmenopausal, Patient Satisfaction, Prospective Studies, Surveys and Questionnaires
Added January 20, 2015
0 Communities
1 Members
0 Resources
17 MeSH Terms
Heritability of spinal trabecular volumetric bone mineral density measured by QCT in the Diabetes Heart Study.
Lenchik L, Hsu FC, Register TC, Lohman KK, Freedman BI, Langefeld CD, Bowden DW, Carr JJ
(2004) Calcif Tissue Int 75: 305-12
MeSH Terms: Absorptiometry, Photon, Adult, Aged, Aged, 80 and over, Bone Density, Diabetes Mellitus, Type 2, Female, Genetic Predisposition to Disease, Humans, Inheritance Patterns, Male, Middle Aged, Nuclear Family, Osteoporosis, Postmenopausal, Spine, Tomography, X-Ray Computed
Added February 15, 2014
0 Communities
1 Members
0 Resources
16 MeSH Terms
[Bone mass regulation by leptin: a hypothalamic control of bone formation].
Elefteriou F, Karsenty G
(2004) Pathol Biol (Paris) 52: 148-53
MeSH Terms: Adipocytes, Adrenergic beta-Antagonists, Animals, Body Weight, Bone Development, Energy Metabolism, Homeostasis, Humans, Immunity, Innate, Leptin, Mice, Mice, Obese, Neurons, Obesity, Organ Size, Osteoblasts, Osteoporosis, Postmenopausal, Receptors, Adrenergic, beta, Receptors, Leptin, Sympathetic Nervous System, Ventromedial Hypothalamic Nucleus
Added November 14, 2013
0 Communities
1 Members
0 Resources
21 MeSH Terms